News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
341,607 Results
Type
Article (20751)
Company Profile (140)
Press Release (320711)
Multimedia
Podcasts (100)
Webinars (17)
Section
Business (105758)
Career Advice (888)
Deals (18604)
Drug Delivery (101)
Drug Development (50975)
Employer Resources (80)
FDA (7797)
Job Trends (7807)
News (186636)
Policy (17447)
Tag
Academia (737)
Accelerated approval (10)
Adcomms (22)
Allergies (69)
Alliances (27969)
ALS (75)
Alzheimer's disease (738)
Antibody-drug conjugate (ADC) (153)
Approvals (7887)
Artificial intelligence (234)
Autoimmune disease (46)
Automation (11)
Bankruptcy (178)
Best Places to Work (5553)
BIOSECURE Act (14)
Biosimilars (136)
Biotechnology (58)
Bladder cancer (65)
Brain cancer (28)
Breast cancer (197)
Cancer (1861)
Cardiovascular disease (196)
Career advice (733)
Career pathing (22)
CAR-T (79)
CDC (14)
Cell therapy (223)
Cervical cancer (10)
Clinical research (44041)
Collaboration (782)
Compensation (301)
Complete response letters (44)
COVID-19 (1140)
CRISPR (42)
C-suite (379)
Cystic fibrosis (80)
Data (2461)
Decentralized trials (2)
Denatured (24)
Depression (57)
Diabetes (215)
Diagnostics (1860)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (22)
Drug discovery (133)
Drug pricing (169)
Drug shortages (33)
Duchenne muscular dystrophy (116)
Earnings (40308)
Editorial (38)
Employer branding (10)
Employer resources (78)
Events (50103)
Executive appointments (601)
FDA (9038)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (524)
Gene editing (76)
Generative AI (24)
Gene therapy (223)
GLP-1 (736)
Government (1980)
Grass and pollen (4)
Guidances (192)
Healthcare (5915)
HIV (21)
Huntington's disease (19)
IgA nephropathy (46)
Immunology and inflammation (142)
Immuno-oncology (14)
Indications (37)
Infectious disease (1252)
Inflammatory bowel disease (107)
Inflation Reduction Act (11)
Influenza (37)
Intellectual property (107)
Interviews (118)
IPO (7415)
IRA (52)
Job creations (2441)
Job search strategy (652)
Kidney cancer (10)
Labor market (54)
Layoffs (334)
Leadership (26)
Legal (4144)
Liver cancer (34)
Longevity (6)
Lung cancer (290)
Lymphoma (152)
Machine learning (15)
Management (31)
Manufacturing (405)
MASH (87)
Medical device (1989)
Medtech (1993)
Mergers & acquisitions (11624)
Metabolic disorders (729)
Multiple sclerosis (82)
NASH (20)
Neurodegenerative disease (111)
Neuropsychiatric disorders (42)
Neuroscience (1311)
NextGen: Class of 2025 (2360)
Non-profit (913)
Now hiring (39)
Obesity (421)
Opinion (219)
Ovarian cancer (53)
Pain (121)
Pancreatic cancer (75)
Parkinson's disease (125)
Partnered (14)
Patents (235)
Patient recruitment (156)
Peanut (19)
People (34140)
Pharmaceutical (76)
Pharmacy benefit managers (28)
Phase I (13825)
Phase II (18587)
Phase III (14959)
Pipeline (1585)
Policy (209)
Postmarket research (1620)
Preclinical (4852)
Press Release (29)
Prostate cancer (114)
Psychedelics (24)
Radiopharmaceuticals (170)
Rare diseases (396)
Real estate (3195)
Recruiting (33)
Regulatory (13262)
Reports (25)
Research institute (826)
Resumes & cover letters (140)
Rett syndrome (3)
RNA editing (8)
RSV (37)
Schizophrenia (100)
Series A (94)
Series B (62)
Service/supplier (7)
Sickle cell disease (50)
Special edition (21)
Spinal muscular atrophy (115)
Sponsored (16)
Startups (2030)
State (2)
Stomach cancer (10)
Supply chain (68)
Tariffs (90)
The Weekly (74)
Vaccines (368)
Venture capital (48)
Weight loss (313)
Women's health (22)
Worklife (8)
Date
Today (79)
Last 7 days (343)
Last 30 days (1334)
Last 365 days (15645)
2025 (12838)
2024 (17678)
2023 (19648)
2022 (25868)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15588)
2017 (17254)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (414)
Alabama (35)
Alaska (1)
Arizona (82)
Arkansas (8)
Asia (25544)
Australia (3291)
California (3959)
Canada (1580)
China (577)
Colorado (160)
Connecticut (166)
Delaware (140)
Europe (52797)
Florida (696)
Georgia (85)
Hawaii (1)
Idaho (17)
Illinois (365)
India (39)
Indiana (255)
Iowa (3)
Japan (237)
Kansas (78)
Kentucky (26)
Louisiana (4)
Maine (4)
Maryland (524)
Massachusetts (3267)
Michigan (60)
Minnesota (204)
Mississippi (3)
Missouri (36)
Montana (11)
Nebraska (11)
Nevada (33)
New Hampshire (8)
New Jersey (1587)
New Mexico (21)
New York (1115)
North Carolina (672)
North Dakota (2)
Northern California (1769)
Ohio (111)
Oklahoma (8)
Oregon (22)
Pennsylvania (915)
Puerto Rico (16)
Rhode Island (23)
South America (611)
South Carolina (8)
Southern California (1661)
Tennessee (53)
Texas (537)
United States (15363)
Utah (82)
Virginia (146)
Washington D.C. (57)
Washington State (317)
West Virginia (1)
Wisconsin (36)
341,607 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Biohaven Grabs a Foothold With $600M Windfall From Oberland Capital
Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, which is currently under FDA review with a decision expected in the third quarter.
April 29, 2025
·
2 min read
·
Tristan Manalac
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
·
7 min read
·
Annalee Armstrong
Legal
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
From March 2020 through September 2022, Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
January 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
August 12, 2025
·
20 min read
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
·
1 min read
·
Dan Samorodnitsky
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
1 of 34,161
Next
